Amylyx Pharmaceuticals Statistics
Total Valuation
AMLX has a market cap or net worth of $1.62 billion. The enterprise value is $1.30 billion.
Important Dates
The last earnings date was Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AMLX has 109.82 million shares outstanding. The number of shares has increased by 24.05% in one year.
| Current Share Class | 109.82M |
| Shares Outstanding | 109.82M |
| Shares Change (YoY) | +24.05% |
| Shares Change (QoQ) | +4.71% |
| Owned by Insiders (%) | 6.57% |
| Owned by Institutions (%) | 78.33% |
| Float | 69.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -2,460.62 |
| Forward PS | n/a |
| PB Ratio | 4.61 |
| P/TBV Ratio | 4.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.70, with a Debt / Equity ratio of 0.02.
| Current Ratio | 13.70 |
| Quick Ratio | 13.35 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -56.52% and return on invested capital (ROIC) is -36.65%.
| Return on Equity (ROE) | -56.52% |
| Return on Assets (ROA) | -32.06% |
| Return on Invested Capital (ROIC) | -36.65% |
| Return on Capital Employed (ROCE) | -46.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.21M |
| Employee Count | 123 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -635,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +177.36% in the last 52 weeks. The beta is -0.33, so AMLX's price volatility has been lower than the market average.
| Beta (5Y) | -0.33 |
| 52-Week Price Change | +177.36% |
| 50-Day Moving Average | 13.64 |
| 200-Day Moving Average | 7.68 |
| Relative Strength Index (RSI) | 62.04 |
| Average Volume (20 Days) | 1,493,382 |
Short Selling Information
The latest short interest is 10.45 million, so 9.52% of the outstanding shares have been sold short.
| Short Interest | 10.45M |
| Short Previous Month | 9.62M |
| Short % of Shares Out | 9.52% |
| Short % of Float | 15.14% |
| Short Ratio (days to cover) | 5.84 |
Income Statement
In the last 12 months, AMLX had revenue of -$665,000 and -$149.28 million in losses. Loss per share was -$1.77.
| Revenue | -665,000 |
| Gross Profit | -56.55M |
| Operating Income | -157.34M |
| Pretax Income | -149.92M |
| Net Income | -149.28M |
| EBITDA | -156.76M |
| EBIT | -157.34M |
| Loss Per Share | -$1.77 |
Full Income StatementBalance Sheet
The company has $343.99 million in cash and $5.94 million in debt, giving a net cash position of $338.06 million or $3.08 per share.
| Cash & Cash Equivalents | 343.99M |
| Total Debt | 5.94M |
| Net Cash | 338.06M |
| Net Cash Per Share | $3.08 |
| Equity (Book Value) | 332.00M |
| Book Value Per Share | 3.02 |
| Working Capital | 327.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$154.45 million and capital expenditures -$36.28 million, giving a free cash flow of -$190.72 million.
| Operating Cash Flow | -154.45M |
| Capital Expenditures | -36.28M |
| Free Cash Flow | -190.72M |
| FCF Per Share | -$1.74 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | 23,660.15% |
| Pretax Margin | 22,543.91% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AMLX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.05% |
| Shareholder Yield | -24.05% |
| Earnings Yield | -9.12% |
| FCF Yield | -11.66% |
Dividend DetailsAnalyst Forecast
The average price target for AMLX is $17.43, which is 18.49% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.43 |
| Price Target Difference | 18.49% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 25.45% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AMLX has an Altman Z-Score of 6.29 and a Piotroski F-Score of 2.
| Altman Z-Score | 6.29 |
| Piotroski F-Score | 2 |
